BIO 030Alternative Names: BIO030
Latest Information Update: 26 Aug 2015
At a glance
- Originator Amilar Pharmaceuticals
- Mechanism of Action Immunomodulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Chronic fatigue syndrome
Most Recent Events
- 30 Aug 2005 Phase-II clinical trials in Chronic fatigue syndrome in USA (unspecified route)